{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:46:47Z","timestamp":1792788407502,"version":"4.5.0"},"reference-count":166,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T00:00:00Z","timestamp":1667865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T00:00:00Z","timestamp":1667865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Natural Science Foundation of Beijing Municipality","award":["7192128"],"award-info":[{"award-number":["7192128"]}]},{"name":"Natural Science Foundation of Beijing Municipality","award":["7172134"],"award-info":[{"award-number":["7172134"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81972688"],"award-info":[{"award-number":["81972688"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"PUMC Youth Fund and Fundamental Research Funds for the Central Universities","award":["2017350002"],"award-info":[{"award-number":["2017350002"]}]},{"name":"PUMC Youth Fund and Fundamental Research Funds for the Central Universities","award":["3332015113"],"award-info":[{"award-number":["3332015113"]}]},{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"crossref","award":["2019ZX09301170"],"award-info":[{"award-number":["2019ZX09301170"]}],"id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"crossref"}]},{"name":"CMAS Innovation Fund for Medical Sciences","award":["2021-I2M-1-026"],"award-info":[{"award-number":["2021-I2M-1-026"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cancer is one of the leading causes of death worldwide due to high heterogeneity. Although chemotherapy remains the mainstay of cancer therapy, non-selective toxicity and drug resistance of mono-chemotherapy incur broad criticisms. Subsequently, various combination strategies have been developed to improve clinical efficacy, also known as cocktail therapy. However, conventional \u201ccocktail administration\u201d is just passable, due to the potential toxicities to normal tissues and unsatisfactory synergistic effects, especially for the combined drugs with different pharmacokinetic properties. The drug conjugates through coupling the conventional chemotherapeutics to a carrier (such as antibody and peptide) provide an alternative strategy to improve therapeutic efficacy and simultaneously reduce the unspecific toxicities, by virtue of the advantages of highly specific targeting ability and potent killing effect. Although 14 antibody\u2013drug conjugates (ADCs) have been approved worldwide and more are being investigated in clinical trials so far, several limitations have been disclosed during clinical application. Compared with ADCs, peptide-drug conjugates (PDCs) possess several advantages, including easy industrial synthesis, low cost, high tissue penetration and fast clearance. So far, only a handful of PDCs have been approved, highlighting tremendous\u00a0development\u00a0potential. Herein, we discuss the progress and pitfalls in the development of ADCs and underline what can learn from ADCs for the better construction of PDCs in the future.<\/jats:p>","DOI":"10.1186\/s40164-022-00347-1","type":"journal-article","created":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T14:04:38Z","timestamp":1667916278000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Learn from antibody\u2013drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy"],"prefix":"10.1186","volume":"11","author":[{"given":"Mo","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,8]]},"reference":[{"key":"347_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"347_CR2","first-page":"391","volume":"74","author":"RJ Papac","year":"2001","unstructured":"Papac RJ. Origins of cancer therapy. Yale J Biol Med. 2001;74:391\u20138.","journal-title":"Yale J Biol Med"},{"issue":"5","key":"347_CR3","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/nrc.2017.17","volume":"17","author":"P Gotwals","year":"2017","unstructured":"Gotwals P, Cameron S, Cipolletta D, Cremasco V, Crystal A, Hewes B, et al. Prospects for combining targeted and conventional cancer therapy with immunotherapy. Nat Rev Cancer. 2017;17(5):286\u2013301.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"347_CR4","first-page":"105","volume":"1805","author":"A Marusyk","year":"2010","unstructured":"Marusyk A, Polyak K. Tumor heterogeneity: causes and consequences. Biochim Biophys Acta. 2010;1805(1):105\u201317.","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"347_CR5","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646\u201374.","journal-title":"Cell"},{"key":"347_CR6","first-page":"251","volume":"107","author":"G Stucchi","year":"2016","unstructured":"Stucchi G, Battevi N, Cairoli S, Consonni D. The hallmarks of cancer. Cell. 2016;107:251\u201362.","journal-title":"Cell"},{"issue":"1","key":"347_CR7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31\u201346.","journal-title":"Cancer Discov"},{"key":"347_CR8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.addr.2015.10.022","volume":"98","author":"Q Hu","year":"2016","unstructured":"Hu Q, Sun W, Wang C, Gu Z. Recent advances of cocktail chemotherapy by combination drug delivery systems. Adv Drug Deliv Rev. 2016;98:19\u201334.","journal-title":"Adv Drug Deliv Rev"},{"issue":"4","key":"347_CR9","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1124\/mi.7.4.8","volume":"7","author":"LD Mayer","year":"2007","unstructured":"Mayer LD, Janoff AS. Optimizing combination chemotherapy by controlling drug ratios. Mol Interv. 2007;7(4):216\u201323.","journal-title":"Mol Interv"},{"issue":"7","key":"347_CR10","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/nbt.1549","volume":"27","author":"J Leh\u00e1r","year":"2009","unstructured":"Leh\u00e1r J, Krueger AS, Avery W, Heilbut AM, Johansen LM, Price ER, et al. Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat Biotechnol. 2009;27(7):659\u201366.","journal-title":"Nat Biotechnol"},{"issue":"4","key":"347_CR11","doi-asserted-by":"publisher","first-page":"669","DOI":"10.3390\/cancers13040669","volume":"13","author":"Y Gilad","year":"2021","unstructured":"Gilad Y, Gellerman G, Lonard DM, O\u2019malley BW. Drug Combination in cancer treatment-from cocktails to conjugated combinations. Cancers (Basel). 2021;13(4):669.","journal-title":"Cancers (Basel)."},{"issue":"6","key":"347_CR12","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","volume":"18","author":"JZ Drago","year":"2021","unstructured":"Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021;18(6):327\u201344.","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"347_CR13","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/d41573-021-00054-2","volume":"20","author":"C Do Pazo","year":"2021","unstructured":"Do Pazo C, Nawaz K, Webster RM. The oncology market for antibody-drug conjugates. Nat Rev Drug Discov. 2021;20(8):583\u20134.","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"347_CR14","doi-asserted-by":"publisher","first-page":"872","DOI":"10.3390\/biomedicines9080872","volume":"9","author":"CM Mckertish","year":"2021","unstructured":"Mckertish CM, Kayser V. Advances and limitations of antibody drug conjugates for cancer. Biomedicines. 2021;9(8):872.","journal-title":"Biomedicines"},{"key":"347_CR15","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.addr.2016.06.015","volume":"110\u201311","author":"Y Wang","year":"2017","unstructured":"Wang Y, Cheetham AG, Angacian G, Su H, Xie L, Cui H. Peptide-drug conjugates as effective prodrug strategies for targeted delivery. Adv Drug Deliv Rev. 2017;110\u201311:112\u201326.","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"347_CR16","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1039\/D0CS00556H","volume":"50","author":"BM Cooper","year":"2021","unstructured":"Cooper BM, Iegre J, O\u2019Donovan DH, \u00d6lweg\u00e5rd Halvarsson M, Spring DR. Peptides as a platform for targeted therapeutics for cancer: Peptide-drug conjugates (PDCs). Chem Soc Rev. 2021;50(3):1480\u201394.","journal-title":"Chem Soc Rev"},{"key":"347_CR17","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1517\/14712598.2012.693473","volume":"12","author":"JR Adair","year":"2012","unstructured":"Adair JR, Howard PW, Hartley JA, Williams DG, Chester KA. Antibody-drug conjugates\u2014a perfect synergy. Expert Opin Biol Ther. 2012;12:1191\u2013206.","journal-title":"Expert Opin Biol Ther"},{"key":"347_CR18","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1093\/jnci\/djz035","volume":"111","author":"MJ Birrer","year":"2019","unstructured":"Birrer MJ, Moore KN, Betella I, Bates RC. Antibody-drug conjugate-based therapeutics: state of the science. J Natl Cancer Inst. 2019;111:538\u201349.","journal-title":"J Natl Cancer Inst"},{"key":"347_CR19","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1038\/bjc.2017.367","volume":"117","author":"AH Staudacher","year":"2017","unstructured":"Staudacher AH, Brown MP. Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required? Br J Cancer. 2017;117:1736\u201342.","journal-title":"Br J Cancer"},{"issue":"5","key":"347_CR20","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nrd.2016.268","volume":"16","author":"A Beck","year":"2017","unstructured":"Beck A, Goetsch L, Dumontet C, Corva\u00efa N. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16(5):315\u201337.","journal-title":"Nat Rev Drug Discov"},{"issue":"11","key":"347_CR21","doi-asserted-by":"publisher","first-page":"3494","DOI":"10.1007\/s11095-015-1624-3","volume":"32","author":"M Damelin","year":"2015","unstructured":"Damelin M, Zhong W, Myers J, Sapra P. Evolving strategies for target selection for antibody-drug conjugates. Pharm Res. 2015;32(11):3494\u2013507.","journal-title":"Pharm Res"},{"issue":"4","key":"347_CR22","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20150089","volume":"35","author":"C Peters","year":"2015","unstructured":"Peters C, Brown S. Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Biosci Rep. 2015;35(4): e00225.","journal-title":"Biosci Rep"},{"key":"347_CR23","doi-asserted-by":"publisher","first-page":"34","DOI":"10.4161\/mabs.27022","volume":"6","author":"S Panowski","year":"2014","unstructured":"Panowski S, Bhakta S, Raab H, Polakis P, Junutula JR. Site-specific antibody drug conjugates for cancer therapy. MAbs. 2014;6:34\u201345.","journal-title":"MAbs"},{"key":"347_CR24","first-page":"217","volume":"27","author":"B Neri","year":"1989","unstructured":"Neri B, Cini-Neri G, Bandinelli M, Pacini P, Bartalucci S, Ciapini A. Doxorubicin and epirubicin cardiotoxicity: experimental and clinical aspects. Int J Clin Pharmacol Ther Toxicol. 1989;27:217\u201321.","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"issue":"11","key":"347_CR25","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1200\/JCO.2000.18.11.2282","volume":"18","author":"MN Saleh","year":"2000","unstructured":"Saleh MN, Sugarman S, Murray J, Ostroff JB, Healey D, Jones D, et al. Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors. J Clin Oncol. 2000;18(11):2282\u201392.","journal-title":"J Clin Oncol"},{"issue":"20","key":"347_CR26","doi-asserted-by":"publisher","first-page":"6064","DOI":"10.1158\/1078-0432.CCR-06-0910","volume":"12","author":"BM Tijink","year":"2006","unstructured":"Tijink BM, Buter J, de Bree R, Giaccone G, Lang MS, Staab A, et al. A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res. 2006;12(20):6064\u201372.","journal-title":"Clin Cancer Res"},{"key":"347_CR27","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.5604\/01.3001.0012.7207","volume":"17","author":"M Lepelley","year":"2018","unstructured":"Lepelley M, Allouchery M, Long J, Boucherle D, Ranchoup Y, Le Marc\u2019Hadour F, et al. Nodular regenerative hyperplasia induced by trastuzumab emtansine: role of emtansine. Ann Hepatol. 2018;17:1067\u201371.","journal-title":"Ann Hepatol"},{"issue":"10","key":"347_CR28","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1097\/ICO.0000000000000868","volume":"35","author":"M Tsuda","year":"2016","unstructured":"Tsuda M, Takano Y, Shigeyasu C, Imoto S, Yamada M. Abnormal corneal lesions induced by trastuzumab emtansine: an antibody-drug conjugate for breast cancer. Cornea. 2016;35(10):1378\u201380.","journal-title":"Cornea"},{"issue":"10","key":"347_CR29","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1002\/cncr.31304","volume":"124","author":"GD Goss","year":"2018","unstructured":"Goss GD, Vokes EE, Gordon MS, Gandhi L, Papadopoulos KP, Rasco DW, et al. Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor. Cancer. 2018;124(10):2174\u201383.","journal-title":"Cancer"},{"issue":"6","key":"347_CR30","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1158\/1078-0432.CCR-18-2474","volume":"25","author":"UA Matulonis","year":"2019","unstructured":"Matulonis UA, Birrer MJ, O\u2019Malley DM, Moore KN, Konner J, Gilbert L, et al. Evaluation of prophylactic corticosteroid eye drop use in the management of corneal abnormalities induced by the antibody-drug conjugate mirvetuximab soravtansine. Clin Cancer Res. 2019;25(6):1727\u201336.","journal-title":"Clin Cancer Res"},{"key":"347_CR31","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/psp4.12192","volume":"6","author":"D Lu","year":"2017","unstructured":"Lu D, Gillespie WR, Girish S, Agarwal P, Li C, Hirata J, et al. Time-to-event analysis of polatuzumab vedotin-induced peripheral neuropathy to assist in the comparison of clinical dosing regimens. CPT Pharmacomet Syst Pharmacol. 2017;6:401\u20138.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"3","key":"347_CR32","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1021\/bc7004329","volume":"19","author":"SC Alley","year":"2008","unstructured":"Alley SC, Benjamin DR, Jeffrey SC, Okeley NM, Meyer DL, Sanderson RJ, et al. Contribution of linker stability to the activities of anticancer immunoconjugates. Bioconjug Chem. 2008;19(3):759\u201365.","journal-title":"Bioconjug Chem"},{"key":"347_CR33","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s11523-017-0535-0","volume":"12","author":"A Nagayama","year":"2017","unstructured":"Nagayama A, Ellisen LW, Chabner B, Bardia A. Antibody-drug conjugates for the treatment of solid tumors: clinical experience and latest developments. Target Oncol. 2017;12:719\u201339.","journal-title":"Target Oncol"},{"key":"347_CR34","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s10637-016-0343-x","volume":"34","author":"AL Coveler","year":"2016","unstructured":"Coveler AL, Ko AH, Catenacci DVT, Von Hoff D, Becerra C, Whiting NC, et al. A phase 1 clinical trial of ASG-5ME, a novel drug-antibody conjugate targeting SLC44A4, in patients with advanced pancreatic and gastric cancers. Invest New Drugs. 2016;34:319\u201328.","journal-title":"Invest New Drugs"},{"key":"347_CR35","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.coi.2016.02.008","volume":"40","author":"BE de Goeij","year":"2016","unstructured":"de Goeij BE, Lambert JM. New developments for antibody-drug conjugate-based therapeutic approaches. Curr Opin Immunol. 2016;40:14\u201323.","journal-title":"Curr Opin Immunol"},{"key":"347_CR36","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1080\/19420862.2016.1156829","volume":"8","author":"H Donaghy","year":"2016","unstructured":"Donaghy H. Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates. MAbs. 2016;8:659\u201371.","journal-title":"MAbs"},{"key":"347_CR37","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1208\/s12248-015-9790-0","volume":"17","author":"MJM Hinrichs","year":"2015","unstructured":"Hinrichs MJM, Dixit R. Antibody drug conjugates: nonclinical safety considerations. AAPS J. 2015;17:1055\u201364.","journal-title":"AAPS J"},{"issue":"18","key":"347_CR38","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","volume":"30","author":"A Younes","year":"2012","unstructured":"Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma. J Clin Oncol. 2012;30(18):2183\u20139.","journal-title":"J Clin Oncol"},{"key":"347_CR39","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1158\/1535-7163.MCT-17-0133","volume":"16","author":"H Zhao","year":"2017","unstructured":"Zhao H, Gulesserian S, Malinao MC, Ganesan SK, Song J, Chang MS, et al. A potential mechanism for ADC-induced neutropenia: role of neutrophils in their own demise. Mol Cancer Ther. 2017;16:1866\u201376.","journal-title":"Mol Cancer Ther"},{"key":"347_CR40","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1016\/j.addr.2012.05.013","volume":"64","author":"D Litvak-Greenfeld","year":"2012","unstructured":"Litvak-Greenfeld D, Benhar I. Risks and untoward toxicities of antibody-based immunoconjugates. Adv Drug Deliv Rev. 2012;64:1782\u201399.","journal-title":"Adv Drug Deliv Rev"},{"key":"347_CR41","doi-asserted-by":"publisher","first-page":"174","DOI":"10.3389\/fnmol.2017.00174","volume":"10","author":"H Starobova","year":"2017","unstructured":"Starobova H, Vetter I. Pathophysiology of chemotherapy-induced peripheral neuropathy. Front Mol Neurosci. 2017;10:174.","journal-title":"Front Mol Neurosci"},{"key":"347_CR42","doi-asserted-by":"publisher","first-page":"1951427","DOI":"10.1080\/19420862.2021.1951427","volume":"13","author":"AQ Dean","year":"2021","unstructured":"Dean AQ, Luo S, Twomey JD, Zhang B. Targeting cancer with antibody-drug conjugates: promises and challenges. MAbs. 2021;13:1951427.","journal-title":"MAbs"},{"key":"347_CR43","doi-asserted-by":"publisher","first-page":"5628","DOI":"10.1002\/jcp.27419","volume":"234","author":"M Abdollahpour-Alitappeh","year":"2019","unstructured":"Abdollahpour-Alitappeh M, Lotfinia M, Gharibi T, Mardaneh J, Farhadihosseinabadi B, Larki P, et al. Antibody-drug conjugates (ADCs) for cancer therapy: strategies, challenges, and successes. J Cell Physiol. 2019;234:5628\u201342.","journal-title":"J Cell Physiol"},{"key":"347_CR44","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s10928-016-9495-8","volume":"43","author":"AP Singh","year":"2016","unstructured":"Singh AP, Sharma S, Shah DK. Quantitative characterization of in vitro bystander effect of antibody-drug conjugates. J Pharmacokinet Pharmacodyn. 2016;43:567\u201382.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"3","key":"347_CR45","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1158\/1078-0432.CCR-09-2069","volume":"16","author":"NM Okeley","year":"2010","unstructured":"Okeley NM, Miyamoto JB, Zhang X, Sanderson RJ, Benjamin DR, Sievers EL, et al. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res. 2010;16(3):888\u201397.","journal-title":"Clin Cancer Res"},{"key":"347_CR46","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1111\/cas.12966","volume":"107","author":"Y Ogitani","year":"2016","unstructured":"Ogitani Y, Hagihara K, Oitate M, Naito H, Agatsuma T. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016;107:1039\u201346.","journal-title":"Cancer Sci"},{"key":"347_CR47","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","volume":"386","author":"J Cort\u00e9s","year":"2022","unstructured":"Cort\u00e9s J, Kim S-B, Chung W-P, Im S-A, Park YH, Hegg R, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med. 2022;386:1143\u201354.","journal-title":"N Engl J Med"},{"key":"347_CR48","doi-asserted-by":"publisher","first-page":"3796","DOI":"10.1002\/anie.201307628","volume":"53","author":"RVJ Chari","year":"2014","unstructured":"Chari RVJ, Miller ML, Widdison WC. Antibody-drug conjugates: an emerging concept in cancer therapy. Angew Chem Int Ed Engl. 2014;53:3796\u2013827.","journal-title":"Angew Chem Int Ed Engl"},{"key":"347_CR49","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1021\/bc0502917","volume":"17","author":"SO Doronina","year":"2006","unstructured":"Doronina SO, Mendelsohn BA, Bovee TD, Cerveny CG, Alley SC, Meyer DL, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem. 2006;17:114\u201324.","journal-title":"Bioconjug Chem"},{"issue":"2","key":"347_CR50","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1200\/JCO.2003.05.137","volume":"21","author":"AW Tolcher","year":"2003","unstructured":"Tolcher AW, Ochoa L, Hammond LA, Patnaik A, Edwards T, Takimoto C, et al. Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study. J Clin Oncol. 2003;21(2):211\u201322.","journal-title":"J Clin Oncol"},{"issue":"1","key":"347_CR51","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1158\/1078-0432.CCR-14-2093","volume":"21","author":"H Uppal","year":"2015","unstructured":"Uppal H, Doudement E, Mahapatra K, Darbonne WC, Bumbaca D, Shen B-Q, et al. Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1). Clin Cancer Res. 2015;21(1):123\u201333.","journal-title":"Clin Cancer Res"},{"key":"347_CR52","first-page":"682","volume":"5","author":"KMK Sand","year":"2014","unstructured":"Sand KMK, Bern M, Nilsen J, Noordzij HT, Sandlie I, Andersen JT. Unraveling the interaction between FcRn and albumin: opportunities for design of albumin-based therapeutics. Front Immunol. 2014;5:682.","journal-title":"Front Immunol"},{"issue":"7","key":"347_CR53","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1158\/1078-0432.CCR-16-0939","volume":"23","author":"M Guffroy","year":"2017","unstructured":"Guffroy M, Falahatpisheh H, Biddle K, Kreeger J, Obert L, Walters K, et al. Liver microvascular injury and thrombocytopenia of antibody-calicheamicin conjugates in cynomolgus monkeys-mechanism and monitoring. Clin Cancer Res. 2017;23(7):1760\u201370.","journal-title":"Clin Cancer Res"},{"key":"347_CR54","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1158\/0008-5472.CAN-17-3671","volume":"78","author":"S Garc\u00eda-Alonso","year":"2018","unstructured":"Garc\u00eda-Alonso S, Oca\u00f1a A, Pandiella A. Resistance to antibody\u2013drug conjugates. Cancer Res. 2018;78:2159\u201365.","journal-title":"Cancer Res"},{"key":"347_CR55","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1158\/1535-7163.MCT-15-0036","volume":"14","author":"R Chen","year":"2015","unstructured":"Chen R, Hou J, Newman E, Kim Y, Donohue C, Liu X, et al. CD30 downregulation, MMAE resistance, and MDR1 upregulation are all associated with resistance to brentuximab vedotin. Mol Cancer Ther. 2015;14:1376\u201384.","journal-title":"Mol Cancer Ther"},{"key":"347_CR56","first-page":"1003","volume":"10","author":"Y Endo","year":"2018","unstructured":"Endo Y, Shen Y, Youssef LA, Mohan N, Wu WJ. T-DM1-resistant cells gain high invasive activity via EGFR and integrin cooperated pathways. MAbs. 2018;10:1003\u201317.","journal-title":"MAbs"},{"key":"347_CR57","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1158\/1535-7163.MCT-16-0408","volume":"15","author":"F Loganzo","year":"2016","unstructured":"Loganzo F, Sung M, Gerber H-P. Mechanisms of resistance to antibody-drug conjugates. Mol Cancer Ther. 2016;15:2825\u201334.","journal-title":"Mol Cancer Ther"},{"key":"347_CR58","doi-asserted-by":"publisher","first-page":"749","DOI":"10.3389\/fphar.2019.00749","volume":"10","author":"P Liu-Kreyche","year":"2019","unstructured":"Liu-Kreyche P, Shen H, Marino AM, Iyer RA, Humphreys WG, Lai Y. Lysosomal P-gp-MDR1 confers drug resistance of brentuximab vedotin and its cytotoxic payload Monomethyl Auristatin E in tumor cells. Front Pharmacol. 2019;10:749.","journal-title":"Front Pharmacol"},{"key":"347_CR59","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.3390\/cancers11091323","volume":"11","author":"T Boyer","year":"2019","unstructured":"Boyer T, Gonzales F, Barth\u00e9l\u00e9my A, Marceau-Renaut A, Peyrouze P, Guihard S, et al. Clinical significance of ABCB1 in acute myeloid leukemia: a comprehensive study. Cancers (Basel). 2019;11:1323.","journal-title":"Cancers (Basel)."},{"issue":"10","key":"347_CR60","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.tips.2021.07.001","volume":"42","author":"YS Zhu","year":"2021","unstructured":"Zhu YS, Tang K, Lv J. Peptide-drug conjugate-based novel molecular drug delivery system in cancer. Trends Pharmacol Sci. 2021;42(10):857\u201369.","journal-title":"Trends Pharmacol Sci"},{"issue":"11","key":"347_CR61","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1080\/17474124.2019.1685381","volume":"13","author":"S Das","year":"2019","unstructured":"Das S, Al-Toubah T, El-Haddad G, Strosberg J. 177Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors. Expert Rev Gastroenterol Hepatol. 2019;13(11):1023\u201331.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"10","key":"347_CR62","doi-asserted-by":"publisher","first-page":"3120","DOI":"10.3390\/jcm9103120","volume":"9","author":"MV Mateos","year":"2020","unstructured":"Mateos MV, Blad\u00e9 J, Bringhen S, Ocio EM, Efebera Y, Pour L, et al. Melflufen: a peptide-drug conjugate for the treatment of multiple myeloma. J Clin Med. 2020;9(10):3120.","journal-title":"J Clin Med"},{"key":"347_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2022.101374","volume":"18","author":"T Olivier","year":"2022","unstructured":"Olivier T, Prasad V. The approval and withdrawal of melphalan flufenamide (melflufen): implications for the state of the FDA. Transl Oncol. 2022;18: 101374.","journal-title":"Transl Oncol"},{"key":"347_CR64","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264299","author":"AA Hofling","year":"2022","unstructured":"Hofling AA, Fotenos AF, Niu G, Fallah J, Agrawal S, Wang SJ, et al. Prostate cancer theragnostic: concurrent approvals by the Food and Drug Administration of the first diagnostic imaging drug indicated to select patients for a paired radioligand therapeutic drug. J Nucl Med. 2022. https:\/\/doi.org\/10.2967\/jnumed.122.264299.","journal-title":"J Nucl Med"},{"issue":"4","key":"347_CR65","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s40291-022-00594-2","volume":"26","author":"SJ Keam","year":"2022","unstructured":"Keam SJ. Lutetium Lu 177 vipivotide tetraxetan: first approval. Mol Diagn Ther. 2022;26(4):467\u201375.","journal-title":"Mol Diagn Ther"},{"issue":"2","key":"347_CR66","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/nbt1190","volume":"24","author":"PM Watt","year":"2006","unstructured":"Watt PM. Screening for peptide drugs from the natural repertoire of biodiverse protein folds. Nat Biotechnol. 2006;24(2):177\u201383.","journal-title":"Nat Biotechnol"},{"key":"347_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2021.114044","volume":"180","author":"M Zorko","year":"2022","unstructured":"Zorko M, Jones S, Langel \u00dc. Cell-penetrating peptides in protein mimicry and cancer therapeutics. Adv Drug Deliv Rev. 2022;180: 114044.","journal-title":"Adv Drug Deliv Rev"},{"issue":"12","key":"347_CR68","doi-asserted-by":"publisher","first-page":"5516","DOI":"10.1039\/C9BM01183H","volume":"7","author":"X Liu","year":"2019","unstructured":"Liu X, Liu J, Liu D, Han Y, Xu H, Liu L, et al. A cell-penetrating peptide-assisted nanovaccine promotes antigen cross-presentation and anti-tumor immune response. Biomater Sci. 2019;7(12):5516\u201327.","journal-title":"Biomater Sci"},{"key":"347_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.120405","volume":"598","author":"B Wu","year":"2021","unstructured":"Wu B, Li M, Li K, Hong W, Lv Q, Li Y, et al. Cell penetrating peptide TAT-functionalized liposomes for efficient ophthalmic delivery of flurbiprofen: Penetration and its underlying mechanism, retention, anti-inflammation and biocompatibility. Int J Pharm. 2021;598: 120405.","journal-title":"Int J Pharm"},{"issue":"2","key":"347_CR70","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3390\/biom10020217","volume":"10","author":"J Geng","year":"2020","unstructured":"Geng J, Guo X, Wang L, Nguyen RQ, Wang F, Liu C, et al. Intracellular delivery of DNA and protein by a novel cell-permeable peptide derived from DOT1L. Biomolecules. 2020;10(2):217.","journal-title":"Biomolecules"},{"key":"347_CR71","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.jconrel.2015.09.067","volume":"219","author":"S Girirajan","year":"2015","unstructured":"Girirajan S, Campbell C, Eichler E. Novel delivery approaches for cancer therapeutics. J Control Release. 2015;219:248\u201368.","journal-title":"J Control Release"},{"key":"347_CR72","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ejpb.2017.08.011","volume":"120","author":"N Zhou","year":"2017","unstructured":"Zhou N, Wu J, Qin YY, Zhao XL, Ding Y, Sun LS, et al. Novel peptide MT23 for potent penetrating and selective targeting in mouse melanoma cancer cells. Eur J Pharm Biopharm. 2017;120:80\u20138.","journal-title":"Eur J Pharm Biopharm"},{"key":"347_CR73","doi-asserted-by":"publisher","first-page":"930","DOI":"10.3762\/bjoc.14.80","volume":"14","author":"EI Vrettos","year":"2018","unstructured":"Vrettos EI, Mez\u0151 G, Tzakos AG. On the design principles of peptide-drug conjugates for targeted drug delivery to the malignant tumor site. Beilstein J Org Chem. 2018;14:930\u201354.","journal-title":"Beilstein J Org Chem"},{"issue":"6","key":"347_CR74","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/ddr.21399","volume":"78","author":"Y Sun","year":"2017","unstructured":"Sun Y, Kang C, Liu F, Zhou Y, Luo L, Qiao H. RGD peptide-based target drug delivery of doxorubicin nanomedicine. Drug Dev Res. 2017;78(6):283\u201391.","journal-title":"Drug Dev Res"},{"issue":"1","key":"347_CR75","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrc2748","volume":"10","author":"JS Desgrosellier","year":"2010","unstructured":"Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10(1):9\u201322.","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"347_CR76","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1016\/j.apsb.2021.01.004","volume":"11","author":"M Li","year":"2021","unstructured":"Li M, Wang Y, Li M, Wu X, Setrerrahmane S, Xu H. Integrins as attractive targets for cancer therapeutics. Acta Pharm Sin B. 2021;11(9):2726\u201337.","journal-title":"Acta Pharm Sin B"},{"issue":"18","key":"347_CR77","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.4155\/fmc-2018-0174","volume":"10","author":"T Chatzisideri","year":"2018","unstructured":"Chatzisideri T, Leonidis G, Sarli V. Cancer-targeted delivery systems based on peptides. Future Med Chem. 2018;10(18):2201\u201326.","journal-title":"Future Med Chem"},{"issue":"8","key":"347_CR78","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0232917","volume":"15","author":"KY Park","year":"2020","unstructured":"Park KY, Kim J. Cyclic pentapeptide cRGDfK enhances the inhibitory effect of sunitinib on TGF-\u03b21-induced epithelial-to-mesenchymal transition in human non-small cell lung cancer cells. PLoS ONE. 2020;15(8): e0232917.","journal-title":"PLoS ONE"},{"issue":"3","key":"347_CR79","doi-asserted-by":"publisher","first-page":"339","DOI":"10.2217\/fon.11.8","volume":"7","author":"DA Reardon","year":"2011","unstructured":"Reardon DA, Neyns B, Weller M, Tonn JC, Nabors LB, Stupp R. Cilengitide: an RGD pentapeptide \u03b1\u03bd\u03b23 and \u03b1\u03bd\u03b25 integrin inhibitor in development for glioblastoma and other malignancies. Futur Oncol. 2011;7(3):339\u201354.","journal-title":"Futur Oncol"},{"issue":"24","key":"347_CR80","doi-asserted-by":"publisher","first-page":"9511","DOI":"10.3390\/ijms21249511","volume":"21","author":"F Fontana","year":"2020","unstructured":"Fontana F, Marzagalli M, Montagnani Marelli M, Raimondi M, Moretti RM, Limonta P. Gonadotropin-releasing hormone receptors in prostate cancer: molecular aspects and biological functions. Int J Mol Sci. 2020;21(24):9511.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"347_CR81","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/PGP.0b013e318178e54f","volume":"28","author":"YT Jeon","year":"2009","unstructured":"Jeon YT, Kim YB, Park SY, Kim JW, Park NH, Kang SB, et al. Gonadotropin-releasing hormone receptor expression in endometrial cancer. Int J Gynecol Pathol. 2009;28(1):19\u201322.","journal-title":"Int J Gynecol Pathol"},{"issue":"2","key":"347_CR82","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3390\/cells10020437","volume":"10","author":"C Gr\u00fcndker","year":"2021","unstructured":"Gr\u00fcndker C, Emons G. Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer. Cells. 2021;10(2):437.","journal-title":"Cells"},{"issue":"3","key":"347_CR83","doi-asserted-by":"publisher","first-page":"258","DOI":"10.2174\/1389557516666161013111155","volume":"17","author":"X Li","year":"2017","unstructured":"Li X, Taratula O, Taratula O, Schumann C, Minko T. LHRH-targeted drug delivery systems for cancer therapy. Mini Rev Med Chem. 2017;17(3):258\u201367.","journal-title":"Mini Rev Med Chem"},{"issue":"11","key":"347_CR84","doi-asserted-by":"publisher","first-page":"R251","DOI":"10.1530\/ERC-20-0442","volume":"28","author":"HSA Ghaly","year":"2021","unstructured":"Ghaly HSA, Varamini P. New drug delivery strategies targeting the GnRH receptor in breast and other cancers. Endocr Relat Cancer. 2021;28(11):R251\u201369.","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"347_CR85","doi-asserted-by":"publisher","first-page":"8212","DOI":"10.1038\/s41598-020-64979-1","volume":"10","author":"JD Obayemi","year":"2020","unstructured":"Obayemi JD, Salifu AA, Eluu SC, Uzonwanne VO, Jusu SM, Nwazojie CC, et al. LHRH-conjugated drugs as targeted therapeutic agents for the specific targeting and localized treatment of triple negative breast cancer. Sci Rep. 2020;10(1):8212.","journal-title":"Sci Rep"},{"key":"347_CR86","doi-asserted-by":"publisher","first-page":"571","DOI":"10.3389\/fchem.2020.00571","volume":"8","author":"P Hoppenz","year":"2020","unstructured":"Hoppenz P, Els-Heindl S, Beck-Sickinger AG. Peptide-drug conjugates and their targets in advanced cancer therapies. Front Chem. 2020;8:571.","journal-title":"Front Chem"},{"issue":"1","key":"347_CR87","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.semradonc.2020.07.010","volume":"31","author":"LB Solnes","year":"2021","unstructured":"Solnes LB, Shokeen M, Pandit-Taskar N. Agents and future perspectives on theranostics. Semin Radiat Oncol. 2021;31(1):83\u201392.","journal-title":"Semin Radiat Oncol"},{"key":"347_CR88","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/967347","volume":"2012","author":"J Thundimadathil","year":"2012","unstructured":"Thundimadathil J. Cancer treatment using peptides: current therapies and future prospects. J Amino Acids. 2012;2012: 967347.","journal-title":"J Amino Acids"},{"issue":"1","key":"347_CR89","doi-asserted-by":"publisher","first-page":"757","DOI":"10.18632\/oncotarget.12748","volume":"8","author":"B Redko","year":"2017","unstructured":"Redko B, Tuchinsky H, Segal T, Tobi D, Luboshits G, Ashur-Fabian O, et al. Toward the development of a novel non-RGD cyclic peptide drug conjugate for treatment of human metastatic melanoma. Oncotarget. 2017;8(1):757\u201368.","journal-title":"Oncotarget"},{"issue":"1","key":"347_CR90","doi-asserted-by":"publisher","first-page":"2","DOI":"10.2174\/156720111793663633","volume":"8","author":"L-C Sun","year":"2011","unstructured":"Sun L-C, Coy DH. Somatostatin receptor-targeted anti-cancer therapy. Curr Drug Deliv. 2011;8(1):2\u201310.","journal-title":"Curr Drug Deliv"},{"issue":"43","key":"347_CR91","doi-asserted-by":"publisher","first-page":"4968","DOI":"10.1039\/c3cc41896k","volume":"49","author":"R Lin","year":"2013","unstructured":"Lin R, Cheetham AG, Zhang P, Lin Y, Cui H. Supramolecular filaments containing a fixed 41% paclitaxel loading. Chem Commun (Camb). 2013;49(43):4968\u201370.","journal-title":"Chem Commun (Camb)"},{"issue":"2","key":"347_CR92","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1158\/1078-0432.CCR-15-1166","volume":"22","author":"B Shor","year":"2016","unstructured":"Shor B, Kahler J, Dougher M, Xu J, Mack M, Rosfjord E, et al. Enhanced antitumor activity of an anti-5T4 antibody-drug conjugate in combination with PI3K\/mTOR inhibitors or taxanes. Clin Cancer Res. 2016;22(2):383\u201394.","journal-title":"Clin Cancer Res"},{"key":"347_CR93","first-page":"599","volume":"13","author":"P Sondergeld","year":"2015","unstructured":"Sondergeld P, van de Donk NWCJ, Richardson PG, Plesner T. Monoclonal antibodies in myeloma. Clin Adv Hematol Oncol. 2015;13:599\u2013609.","journal-title":"Clin Adv Hematol Oncol"},{"key":"347_CR94","doi-asserted-by":"publisher","first-page":"42081","DOI":"10.18632\/oncotarget.5877","volume":"6","author":"EJ Ter Weele","year":"2015","unstructured":"Ter Weele EJ, Terwisscha van Scheltinga AGT, Kosterink JGW, Pot L, Vedelaar SR, Lamberts LE, et al. Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with 89Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts. Oncotarget. 2015;6:42081\u201390.","journal-title":"Oncotarget"},{"key":"347_CR95","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.39","volume":"5","author":"SY Kim","year":"2015","unstructured":"Kim SY, Theunissen J-W, Balibalos J, Liao-Chan S, Babcock MC, Wong T, et al. A novel antibody-drug conjugate targeting SAIL for the treatment of hematologic malignancies. Blood Cancer J. 2015;5: e316.","journal-title":"Blood Cancer J"},{"key":"347_CR96","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1158\/1535-7163.MCT-15-0067","volume":"14","author":"DS Pereira","year":"2015","unstructured":"Pereira DS, Guevara CI, Jin L, Mbong N, Verlinsky A, Hsu SJ, et al. AGS67E, an anti-CD37 monomethyl Auristatin E antibody-drug conjugate as a potential therapeutic for B\/T-cell malignancies and AML: a new role for CD37 in AML. Mol Cancer Ther. 2015;14:1650\u201360.","journal-title":"Mol Cancer Ther"},{"key":"347_CR97","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1158\/0008-5472.CAN-13-2990","volume":"74","author":"E Perrino","year":"2014","unstructured":"Perrino E, Steiner M, Krall N, Bernardes GJL, Pretto F, Casi G, et al. Curative properties of noninternalizing antibody-drug conjugates based on maytansinoids. Cancer Res. 2014;74:2569\u201378.","journal-title":"Cancer Res"},{"key":"347_CR98","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1172\/JCI120481","volume":"128","author":"C Szot","year":"2018","unstructured":"Szot C, Saha S, Zhang XM, Zhu Z, Hilton MB, Morris K, et al. Tumor stroma-targeted antibody-drug conjugate triggers localized anticancer drug release. J Clin Invest. 2018;128:2927\u201343.","journal-title":"J Clin Invest"},{"key":"347_CR99","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.jconrel.2017.08.040","volume":"264","author":"A Dal Corso","year":"2017","unstructured":"Dal Corso A, G\u00e9bleux R, Murer P, Soltermann A, Neri D. A non-internalizing antibody-drug conjugate based on an anthracycline payload displays potent therapeutic activity in vivo. J Control Release. 2017;264:211\u20138.","journal-title":"J Control Release"},{"key":"347_CR100","first-page":"525","volume":"4","author":"X Wu","year":"2014","unstructured":"Wu X, Yu G, Lindner D, Brady-Kalnay SM, Zhang Q, Lu Z-R. Peptide targeted high-resolution molecular imaging of prostate cancer with MRI. Am J Nucl Med Mol Imaging. 2014;4:525\u201336.","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"347_CR101","doi-asserted-by":"publisher","first-page":"8692","DOI":"10.1021\/jp711477k","volume":"112","author":"D Zanuy","year":"2008","unstructured":"Zanuy D, Flores-Ortega A, Casanovas J, Curc\u00f3 D, Nussinov R, Alem\u00e1n C. The energy landscape of a selective tumor-homing pentapeptide. J Phys Chem B. 2008;112:8692\u2013700.","journal-title":"J Phys Chem B"},{"key":"347_CR102","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1016\/j.actbio.2014.01.025","volume":"10","author":"AM Kruse","year":"2014","unstructured":"Kruse AM, Meenach SA, Anderson KW, Hilt JZ. Synthesis and characterization of CREKA-conjugated iron oxide nanoparticles for hyperthermia applications. Acta Biomater. 2014;10:2622\u20139.","journal-title":"Acta Biomater"},{"key":"347_CR103","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1073\/pnas.0610298104","volume":"104","author":"D Simberg","year":"2007","unstructured":"Simberg D, Duza T, Park JH, Essler M, Pilch J, Zhang L, et al. Biomimetic amplification of nanoparticle homing to tumors. Proc Natl Acad Sci U S A. 2007;104:932\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"347_CR104","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.jconrel.2014.05.035","volume":"187","author":"A Barve","year":"2014","unstructured":"Barve A, Jin W, Cheng K. Prostate cancer relevant antigens and enzymes for targeted drug delivery. J Control Release. 2014;187:118\u201332.","journal-title":"J Control Release"},{"key":"347_CR105","doi-asserted-by":"publisher","first-page":"91","DOI":"10.4331\/wjbc.v4.i4.91","volume":"4","author":"G-J Tan","year":"2013","unstructured":"Tan G-J, Peng Z-K, Lu J-P, Tang F-Q. Cathepsins mediate tumor metastasis. World J Biol Chem. 2013;4:91\u2013101.","journal-title":"World J Biol Chem"},{"key":"347_CR106","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.2967\/jnumed.115.171553","volume":"57","author":"NP Withana","year":"2016","unstructured":"Withana NP, Saito T, Ma X, Garland M, Liu C, Kosuge H, et al. Dual-modality activity-based probes as molecular imaging agents for vascular inflammation. J Nucl Med. 2016;57:1583\u201390.","journal-title":"J Nucl Med"},{"issue":"3","key":"347_CR107","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1093\/jmcb\/mjv038","volume":"7","author":"L Chen","year":"2015","unstructured":"Chen L, Wu J. Bio-network medicine. J Mol Cell Biol. 2015;7(3):185\u20136.","journal-title":"J Mol Cell Biol"},{"key":"347_CR108","doi-asserted-by":"publisher","first-page":"6993","DOI":"10.1038\/s41598-017-07481-5","volume":"7","author":"M Ghanat Bari","year":"2017","unstructured":"Ghanat Bari M, Ung CY, Zhang C, Zhu S, Li H. Machine learning-assisted network inference approach to identify a new class of genes that coordinate the functionality of cancer networks. Sci Rep. 2017;7:6993.","journal-title":"Sci Rep"},{"key":"347_CR109","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1093\/bib\/bbaa257","volume":"22","author":"G Muzio","year":"2021","unstructured":"Muzio G, O\u2019Bray L, Borgwardt K. Biological network analysis with deep learning. Brief Bioinform. 2021;22:1515\u201330.","journal-title":"Brief Bioinform"},{"key":"347_CR110","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/j.cell.2018.05.015","volume":"173","author":"DM Camacho","year":"2018","unstructured":"Camacho DM, Collins KM, Powers RK, Costello JC, Collins JJ. Next-generation machine learning for biological networks. Cell. 2018;173:1581\u201392.","journal-title":"Cell"},{"issue":"7","key":"347_CR111","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0200717","volume":"13","author":"M Kori","year":"2018","unstructured":"Kori M, Yalcin AK. Potential biomarkers and therapeutic targets in cervical cancer: insights from the meta-analysis of transcriptomics data within network biomedicine perspective. PLoS ONE. 2018;13(7): e0200717.","journal-title":"PLoS ONE"},{"key":"347_CR112","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/bib\/bbz134","volume":"22","author":"L Zhang","year":"2021","unstructured":"Zhang L, Dai Z, Yu J, Xiao M. CpG-island-based annotation and analysis of human housekeeping genes. Brief Bioinform. 2021;22:515\u201325.","journal-title":"Brief Bioinform"},{"key":"347_CR113","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s12859-019-2741-5","volume":"20","author":"L Zhang","year":"2019","unstructured":"Zhang L, Li J, Yin K, Jiang Z, Li T, Hu R, et al. Computed tomography angiography-based analysis of high-risk intracerebral haemorrhage patients by employing a mathematical model. BMC Bioinformatics. 2019;20:193.","journal-title":"BMC Bioinformatics"},{"key":"347_CR114","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/s41586-019-1103-9","volume":"568","author":"FM Behan","year":"2019","unstructured":"Behan FM, Iorio F, Picco G, Gon\u00e7alves E, Beaver CM, Migliardi G, et al. Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens. Nature. 2019;568:511\u20136.","journal-title":"Nature"},{"key":"347_CR115","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.ejmech.2018.12.035","volume":"163","author":"C Zhuang","year":"2019","unstructured":"Zhuang C, Guan X, Ma H, Cong H, Zhang W, Miao Z. Small molecule-drug conjugates: a novel strategy for cancer-targeted treatment. Eur J Med Chem. 2019;163:883\u201395.","journal-title":"Eur J Med Chem"},{"key":"347_CR116","doi-asserted-by":"publisher","first-page":"8751","DOI":"10.1021\/acs.jmedchem.5b00457","volume":"58","author":"G Casi","year":"2015","unstructured":"Casi G, Neri D. Antibody-drug conjugates and small molecule-drug conjugates: opportunities and challenges for the development of selective anticancer cytotoxic agents. J Med Chem. 2015;58:8751\u201361.","journal-title":"J Med Chem"},{"issue":"1","key":"347_CR117","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.drudis.2014.10.003","volume":"20","author":"K Fosgerau","year":"2015","unstructured":"Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. Drug Discov Today. 2015;20(1):122\u20138.","journal-title":"Drug Discov Today"},{"key":"347_CR118","doi-asserted-by":"publisher","first-page":"19","DOI":"10.4062\/biomolther.2012.20.1.019","volume":"20","author":"SH Joo","year":"2012","unstructured":"Joo SH. Cyclic peptides as therapeutic agents and biochemical tools. Biomol Ther (Seoul). 2012;20:19\u201326.","journal-title":"Biomol Ther (Seoul)"},{"issue":"10","key":"347_CR119","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.3390\/ijms20102383","volume":"20","author":"AC-L Lee","year":"2019","unstructured":"Lee AC-L, Harris JL, Khanna KK, Hong J-H. Comprehensive review on current advances in peptide drug development and design. Int J Mol Sci. 2019;20(10):2383.","journal-title":"Int J Mol Sci"},{"key":"347_CR120","doi-asserted-by":"publisher","first-page":"4348","DOI":"10.1039\/C7TB00318H","volume":"5","author":"M Roveri","year":"2017","unstructured":"Roveri M, Bernasconi M, Leroux J-C, Luciani P. Peptides for tumor-specific drug targeting: state of the art and beyond. J Mater Chem B. 2017;5:4348\u201364.","journal-title":"J Mater Chem B"},{"key":"347_CR121","doi-asserted-by":"publisher","first-page":"5577","DOI":"10.1039\/C9SC06383H","volume":"11","author":"S Kannan","year":"2020","unstructured":"Kannan S, Aronica PGA, Ng S, Gek Lian DT, Frosi Y, Chee S, et al. Macrocyclization of an all-d linear \u03b1-helical peptide imparts cellular permeability. Chem Sci. 2020;11:5577\u201391.","journal-title":"Chem Sci"},{"key":"347_CR122","doi-asserted-by":"publisher","first-page":"4107","DOI":"10.1021\/acs.jmedchem.9b02129","volume":"63","author":"GE Mudd","year":"2020","unstructured":"Mudd GE, Brown A, Chen L, van Rietschoten K, Watcham S, Teufel DP, et al. Identification and optimization of EphA2-selective bicycles for the delivery of cytotoxic payloads. J Med Chem. 2020;63:4107\u201316.","journal-title":"J Med Chem"},{"key":"347_CR123","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1158\/1535-7163.MCT-19-1092","volume":"19","author":"G Bennett","year":"2020","unstructured":"Bennett G, Brown A, Mudd G, Huxley P, Van Rietschoten K, Pavan S, et al. MMAE delivery using the bicycle toxin conjugate BT5528. Mol Cancer Ther. 2020;19:1385\u201394.","journal-title":"Mol Cancer Ther"},{"key":"347_CR124","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.2c00065","author":"GE Mudd","year":"2022","unstructured":"Mudd GE, Scott H, Chen L, van Rietschoten K, Ivanova-Berndt G, Dzionek K, et al. Discovery of BT8009: A nectin-4 targeting bicycle toxin conjugate for the treatment of cancer. J Med Chem. 2022. https:\/\/doi.org\/10.1021\/acs.jmedchem.2c00065.","journal-title":"J Med Chem"},{"issue":"11","key":"347_CR125","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002883","volume":"9","author":"K Hurov","year":"2021","unstructured":"Hurov K, Lahdenranta J, Upadhyaya P, Haines E, Cohen H, Repash E, et al. BT7480, a novel fully synthetic Bicycle tumor-targeted immune cell agonist\u2122 (Bicycle TICA\u2122) induces tumor localized CD137 agonism. J Immunother Cancer. 2021;9(11): e002883.","journal-title":"J Immunother Cancer"},{"key":"347_CR126","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s13238-019-0639-7","volume":"10","author":"PE Saw","year":"2019","unstructured":"Saw PE, Song E-W. Phage display screening of therapeutic peptide for cancer targeting and therapy. Protein Cell. 2019;10:787\u2013807.","journal-title":"Protein Cell"},{"key":"347_CR127","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1021\/mp700073y","volume":"4","author":"OH Aina","year":"2007","unstructured":"Aina OH, Liu R, Sutcliffe JL, Marik J, Pan C-X, Lam KS. From combinatorial chemistry to cancer-targeting peptides. Mol Pharm. 2007;4:631\u201351.","journal-title":"Mol Pharm"},{"key":"347_CR128","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1021\/cr9600114","volume":"97","author":"KS Lam","year":"1997","unstructured":"Lam KS, Lebl M, Krchn\u00e1k V. The, \u201cone-bead-one-compound\u201d combinatorial library method. Chem Rev. 1997;97:411\u201348.","journal-title":"Chem Rev"},{"key":"347_CR129","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1021\/cc800145c","volume":"11","author":"MM Marani","year":"2009","unstructured":"Marani MM, Mart\u00ednez Ceron MC, Giudicessi SL, de Oliveira E, C\u00f4t\u00e9 S, Erra-Balsells R, et al. Screening of one-bead-one-peptide combinatorial library using red fluorescent dyes. Presence of positive and false positive beads. J Comb Chem. 2009;11:146\u201350.","journal-title":"J Comb Chem"},{"issue":"20","key":"347_CR130","doi-asserted-by":"publisher","first-page":"6389","DOI":"10.1158\/1078-0432.CCR-11-1417","volume":"17","author":"BA Teicher","year":"2011","unstructured":"Teicher BA, Chari RVJ. Antibody conjugate therapeutics: challenges and potential. Clin Cancer Res. 2011;17(20):6389\u201397.","journal-title":"Clin Cancer Res"},{"key":"347_CR131","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1182\/blood-2013-03-491506","volume":"122","author":"MS Kung Sutherland","year":"2013","unstructured":"Kung Sutherland MS, Walter RB, Jeffrey SC, Burke PJ, Yu C, Kostner H, et al. SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood. 2013;122:1455\u201363.","journal-title":"Blood"},{"key":"347_CR132","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1021\/bc400217g","volume":"24","author":"SC Jeffrey","year":"2013","unstructured":"Jeffrey SC, Burke PJ, Lyon RP, Meyer DW, Sussman D, Anderson M, et al. A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology. Bioconjug Chem. 2013;24:1256\u201363.","journal-title":"Bioconjug Chem"},{"key":"347_CR133","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1158\/1535-7163.MCT-16-0233","volume":"15","author":"MJ Flynn","year":"2016","unstructured":"Flynn MJ, Zammarchi F, Tyrer PC, Akarca AU, Janghra N, Britten CE, et al. ADCT-301, a Pyrrolobenzodiazepine (PBD) dimer-containing antibody-drug conjugate (ADC) targeting CD25-expressing hematological malignancies. Mol Cancer Ther. 2016;15:2709\u201321.","journal-title":"Mol Cancer Ther"},{"key":"347_CR134","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1182\/blood-2017-10-813493","volume":"131","author":"F Zammarchi","year":"2018","unstructured":"Zammarchi F, Corbett S, Adams L, Tyrer PC, Kiakos K, Janghra N, et al. ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies. Blood. 2018;131:1094\u2013105.","journal-title":"Blood"},{"key":"347_CR135","first-page":"1229","volume":"81","author":"A Lee","year":"2021","unstructured":"Lee A. Loncastuximab tesirine: first approval. Drugs New Zealand. 2021;81:1229\u201333.","journal-title":"Drugs New Zealand"},{"key":"347_CR136","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1080\/14712598.2020.1776255","volume":"21","author":"JA Hartley","year":"2021","unstructured":"Hartley JA. Antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) dimers for cancer therapy. Expert Opin Biol Ther. 2021;21:931\u201343.","journal-title":"Expert Opin Biol Ther"},{"key":"347_CR137","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","volume":"382","author":"S Modi","year":"2020","unstructured":"Modi S, Saura C, Yamashita T, Park YH, Kim S-B, Tamura K, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382:610\u201321.","journal-title":"N Engl J Med"},{"key":"347_CR138","doi-asserted-by":"publisher","first-page":"240","DOI":"10.31083\/j.fbl2708240","volume":"27","author":"J Schwach","year":"2022","unstructured":"Schwach J, Abdellatif M, Stengl A. More than toxins-current prospects in designing the next generation of antibody drug conjugates. Front Biosci (Landmark Ed). 2022;27:240.","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"1","key":"347_CR139","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1021\/acs.jmedchem.0c01530","volume":"64","author":"M Alas","year":"2021","unstructured":"Alas M, Saghaeidehkordi A, Kaur K. Peptide-drug conjugates with different linkers for cancer therapy. J Med Chem. 2021;64(1):216\u201332.","journal-title":"J Med Chem"},{"issue":"5","key":"347_CR140","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1007\/s43440-020-00138-7","volume":"72","author":"T Haider","year":"2020","unstructured":"Haider T, Pandey V, Banjare N, Gupta PN, Soni V. Drug resistance in cancer: mechanisms and tackling strategies. Pharmacol Rep. 2020;72(5):1125\u201351.","journal-title":"Pharmacol Rep"},{"key":"347_CR141","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1002\/ijc.30870","volume":"141","author":"N Takegawa","year":"2017","unstructured":"Takegawa N, Nonagase Y, Yonesaka K, Sakai K, Maenishi O, Ogitani Y, et al. DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance. Int J cancer. 2017;141:1682\u20139.","journal-title":"Int J cancer"},{"key":"347_CR142","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1158\/0008-5472.CAN-09-3546","volume":"70","author":"YV Kovtun","year":"2010","unstructured":"Kovtun YV, Audette CA, Mayo MF, Jones GE, Doherty H, Maloney EK, et al. Antibody-maytansinoid conjugates designed to bypass multidrug resistance. Cancer Res. 2010;70:2528\u201337.","journal-title":"Cancer Res"},{"key":"347_CR143","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1158\/1535-7163.MCT-14-1095","volume":"14","author":"O Ab","year":"2015","unstructured":"Ab O, Whiteman KR, Bartle LM, Sun X, Singh R, Tavares D, et al. IMGN853, a folate receptor-\u03b1 (FR\u03b1)-targeting antibody-drug conjugate, exhibits potent targeted antitumor activity against FR\u03b1-expressing tumors. Mol Cancer Ther. 2015;14:1605\u201313.","journal-title":"Mol Cancer Ther"},{"key":"347_CR144","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ccell.2015.12.008","volume":"29","author":"JY Li","year":"2016","unstructured":"Li JY, Perry SR, Muniz-Medina V, Wang X, Wetzel LK, Rebelatto MC, et al. A biparatopic HER2-targeting antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-targeted therapy. Cancer Cell. 2016;29:117\u201329.","journal-title":"Cancer Cell"},{"key":"347_CR145","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1158\/1535-7163.MCT-16-0658","volume":"16","author":"J Andreev","year":"2017","unstructured":"Andreev J, Thambi N, Perez Bay AE, Delfino F, Martin J, Kelly MP, et al. Bispecific Antibodies and antibody-drug conjugates (ADCs) bridging HER2 and prolactin receptor improve efficacy of HER2 ADCs. Mol Cancer Ther. 2017;16:681\u201393.","journal-title":"Mol Cancer Ther"},{"key":"347_CR146","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.113050","volume":"213","author":"X Deng","year":"2021","unstructured":"Deng X, Mai R, Zhang C, Yu D, Ren Y, Li G, et al. Discovery of novel cell-penetrating and tumor-targeting peptide-drug conjugate (PDC) for programmable delivery of paclitaxel and cancer treatment. Eur J Med Chem. 2021;213: 113050.","journal-title":"Eur J Med Chem"},{"issue":"9","key":"347_CR147","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.3390\/ijms21093233","volume":"21","author":"K Bukowski","year":"2020","unstructured":"Bukowski K, Kciuk M, Kontek R. Mechanisms of multidrug resistance in cancer chemotherapy. Int J Mol Sci. 2020;21(9):3233.","journal-title":"Int J Mol Sci"},{"key":"347_CR148","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jconrel.2015.11.029","volume":"221","author":"Y Jiang","year":"2016","unstructured":"Jiang Y, Yang N, Zhang H, Sun B, Hou C, Ji C, et al. Enhanced in vivo antitumor efficacy of dual-functional peptide-modified docetaxel nanoparticles through tumor targeting and Hsp90 inhibition. J Control Release. 2016;221:26\u201336.","journal-title":"J Control Release"},{"issue":"1","key":"347_CR149","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13045-022-01274-8","volume":"15","author":"Y Jiang","year":"2022","unstructured":"Jiang Y, Huang W, Sun X, Yang X, Wu Y, Shi J, et al. DTX-P7, a peptide-drug conjugate, is highly effective for non-small cell lung cancer. J Hematol Oncol. 2022;15(1):73.","journal-title":"J Hematol Oncol"},{"key":"347_CR150","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/s41388-019-1016-y","volume":"39","author":"L Dubrez","year":"2020","unstructured":"Dubrez L, Causse S, Borges Bonan N, Dum\u00e9tier B, Garrido C. Heat-shock proteins: chaperoning DNA repair. Oncogene. 2020;39:516\u201329.","journal-title":"Oncogene"},{"key":"347_CR151","doi-asserted-by":"publisher","first-page":"32622","DOI":"10.18632\/oncotarget.5327","volume":"6","author":"J-Y Ahn","year":"2015","unstructured":"Ahn J-Y, Lee J-S, Min H-Y, Lee H-Y. Acquired resistance to 5-fluorouracil via HSP90\/Src-mediated increase in thymidylate synthase expression in colon cancer. Oncotarget. 2015;6:32622\u201333.","journal-title":"Oncotarget"},{"key":"347_CR152","first-page":"6687","volume":"8","author":"Z Zhang","year":"2015","unstructured":"Zhang Z, Xie Z, Sun G, Yang P, Li J, Yang H, et al. Reversing drug resistance of cisplatin by hsp90 inhibitors in human ovarian cancer cells. Int J Clin Exp Med. 2015;8:6687\u2013701.","journal-title":"Int J Clin Exp Med"},{"issue":"33","key":"347_CR153","doi-asserted-by":"publisher","first-page":"25458","DOI":"10.1074\/jbc.M110.139345","volume":"285","author":"J-S Chen","year":"2010","unstructured":"Chen J-S, Hsu Y-M, Chen C-C, Chen L-L, Lee C-C, Huang T-S. Secreted heat shock protein 90alpha induces colorectal cancer cell invasion through CD91\/LRP-1 and NF-kappaB-mediated integrin alphaV expression. J Biol Chem. 2010;285(33):25458\u201366.","journal-title":"J Biol Chem"},{"key":"347_CR154","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.bbamcr.2011.09.009","volume":"1823","author":"W Li","year":"2012","unstructured":"Li W, Sahu D, Tsen F. Secreted heat shock protein-90 (Hsp90) in wound healing and cancer. Biochim Biophys Acta. 2012;1823:730\u201341.","journal-title":"Biochim Biophys Acta"},{"key":"347_CR155","doi-asserted-by":"publisher","first-page":"21288","DOI":"10.1073\/pnas.0908151106","volume":"106","author":"X Wang","year":"2009","unstructured":"Wang X, Song X, Zhuo W, Fu Y, Shi H, Liang Y, et al. The regulatory mechanism of Hsp90alpha secretion and its function in tumor malignancy. Proc Natl Acad Sci U S A. 2009;106:21288\u201393.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"347_CR156","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1111\/j.1349-7006.2007.00561.x","volume":"98","author":"S Tsutsumi","year":"2007","unstructured":"Tsutsumi S, Neckers L. Extracellular heat shock protein 90: a role for a molecular chaperone in cell motility and cancer metastasis. Cancer Sci. 2007;98:1536\u20139.","journal-title":"Cancer Sci"},{"key":"347_CR157","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.4161\/cc.7.11.6054","volume":"7","author":"K Sidera","year":"2008","unstructured":"Sidera K, Patsavoudi E. Extracellular HSP90: conquering the cell surface. Cell Cycle. 2008;7:1564\u20138.","journal-title":"Cell Cycle"},{"issue":"2","key":"347_CR158","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.tips.2018.12.004","volume":"40","author":"A Recasens","year":"2019","unstructured":"Recasens A, Munoz L. Targeting cancer cell dormancy. Trends Pharmacol Sci. 2019;40(2):128\u201341.","journal-title":"Trends Pharmacol Sci"},{"issue":"2","key":"347_CR159","doi-asserted-by":"publisher","first-page":"101","DOI":"10.4155\/bio-2020-0256","volume":"13","author":"C Gowland","year":"2021","unstructured":"Gowland C, Berry P, Errington J, Jeffrey P, Bennett G, Godfrey L, et al. Development of a LC-MS\/MS method for the quantification of toxic payload DM1 cleaved from BT1718 in a Phase I study. Bioanalysis. 2021;13(2):101\u201313.","journal-title":"Bioanalysis"},{"key":"347_CR160","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2174\/0929867324666170404142840","volume":"24","author":"L Ma","year":"2017","unstructured":"Ma L, Wang C, He Z, Cheng B, Zheng L, Huang K. Peptide-drug conjugate: a novel drug design approach. Curr Med Chem. 2017;24:161.","journal-title":"Curr Med Chem"},{"key":"347_CR161","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1158\/1078-0432.CCR-12-2481","volume":"19","author":"J Drappatz","year":"2013","unstructured":"Drappatz J, Brenner A, Wong ET, Eichler A, Schiff D, Groves MD, et al. Phase I study of GRN1005 in recurrent malignant glioma. Clin Cancer Res. 2013;19:1567\u201376.","journal-title":"Clin Cancer Res"},{"key":"347_CR162","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1517\/13543784.2012.685128","volume":"21","author":"J Engel","year":"2012","unstructured":"Engel J, Emons G, Pinski J, Schally AV. AEZS-108: a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors. Expert Opin Investig Drugs. 2012;21:891\u20139.","journal-title":"Expert Opin Investig Drugs"},{"key":"347_CR163","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1158\/1535-7163.MCT-18-0770","volume":"18","author":"S Ma","year":"2019","unstructured":"Ma S, Pradeep S, Villar-Prados A, Wen Y, Bayraktar E, Mangala LS, et al. GnRH-R-targeted lytic peptide sensitizes BRCA wild-type ovarian cancer to PARP inhibition. Mol Cancer Ther. 2019;18:969\u201379.","journal-title":"Mol Cancer Ther"},{"key":"347_CR164","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1158\/1535-7163.MCT-21-1000","volume":"21","author":"U Jo","year":"2022","unstructured":"Jo U, Murai Y, Agama KK, Sun Y, Saha LK, Yang X, et al. TOP1-DNA Trapping by exatecan and combination therapy with ATR Inhibitor. Mol Cancer Ther. 2022;21:1090\u2013102.","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"347_CR165","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1200\/JCO.2002.07.001","volume":"20","author":"RS DiPaola","year":"2002","unstructured":"DiPaola RS, Rinehart J, Nemunaitis J, Ebbinghaus S, Rubin E, Capanna T, et al. Characterization of a novel prostate-specific antigen-activated peptide-doxorubicin conjugate in patients with prostate cancer. J Clin Oncol. 2002;20(7):1874\u20139.","journal-title":"J Clin Oncol"},{"key":"347_CR166","doi-asserted-by":"publisher","first-page":"2708","DOI":"10.1021\/acs.jmedchem.8b02036","volume":"62","author":"BH White","year":"2019","unstructured":"White BH, Whalen K, Kriksciukaite K, Alargova R, Au Yeung T, Bazinet P, et al. Discovery of an SSTR2-targeting maytansinoid conjugate (PEN-221) with potent activity in vitro and in vivo. J Med Chem. 2019;62:2708\u201319.","journal-title":"J Med Chem"}],"container-title":["Experimental Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-022-00347-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-022-00347-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-022-00347-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T23:35:23Z","timestamp":1668123323000},"score":1,"resource":{"primary":{"URL":"https:\/\/ehoonline.biomedcentral.com\/articles\/10.1186\/s40164-022-00347-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,8]]},"references-count":166,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["347"],"URL":"https:\/\/doi.org\/10.1186\/s40164-022-00347-1","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,8]]},"assertion":[{"value":"4 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate:"}},{"value":"All authors have read and approved the final manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"93"}}